EFFICACY AND SAFETY OF EVEROLIMUS IN COMBINATION WITH REDUCED TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: 36-MONTH RESULTS FROM THE RANDOMIZED H2304 STUDY

被引：0
|
作者：
Saliba, F. [1 ]
Duvoux, C. [2 ]
Durand, F. [3 ]
Neau-Cransac, M. [4 ]
Hardwigsen, J. [5 ]
Pageaux, G. [6 ]
Di Giambattista, F. [7 ]
机构：
[1] Hop Paul Brousse, Villejuif, France
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Hop Beaujon, Clichy, France
[4] Hop Pellegrin, F-33076 Bordeaux, France
[5] Hop Conception, Marseille, France
[6] Hop St Eloi, Montpellier, France
[7] Novartis Pharma SAS, Rueil Malmaison, France
来源：
TRANSPLANT INTERNATIONAL | 2015年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
74
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy Profile of Everolimus With Reduced Tacrolimus in Living Donor Liver Transplant Recipients-12-month Results From the Pivotal H2307 Study
    Maluf, Daniel
    Jeng, Long-Bin
    Lee, Sung Gyu
    Soin, Arvinder S.
    Lee, Wei Chen
    Emond, Jean
    Lim, Kieron B.
    Lopez, Patricia M.
    Kochuparampil, Jossy
    Sips, Carole A.
    Kaneko, Shuhei
    Grant, David
    HEPATOLOGY, 2017, 66 : 901A - 901A
  • [32] Efficacy and Safety of Everolimus With Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplant: Design of a Randomized Study
    Grant, D.
    Levy, G.
    Song, G.
    Chen, C.
    Lee, W.
    Joh, J.
    Speziale, A.
    Rauer, B.
    Wang, Z.
    Junge, G.
    Uemoto, S.
    Suh, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 781 - 782
  • [33] Efficacy and Safety of Everolimus with Early Reduction or Elimination of Tacrolimus in 719 de Novo Liver Transplant Recipients - Results at 12 Months
    De Simone, P.
    Nevens, F.
    Duvoux, C.
    Koneru, B.
    McCormack, L.
    McCaughan, G.
    Navasa, M.
    Dong, G.
    Hexham, J. M.
    Junge, G.
    Fung, J.
    TRANSPLANTATION, 2012, 94 (10) : 220 - 220
  • [34] Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
    De Simone, P.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fung, J.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Koneru, B.
    Huang, M. A.
    Chapman, W. C.
    Foltys, D.
    Witte, S.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (11) : 3008 - 3020
  • [35] Everolimus Safety Profile in Liver Transplant Recipients With 3-Year Exposure in the H2304 Core and Extension Study.
    Saliba, F.
    Rogiers, X.
    Chapman, W.
    Caicedo, L.
    Alsina, A.
    Teperman, L.
    Junge, G.
    Rauer, B.
    Dong, G.
    De Simone, P.
    LIVER TRANSPLANTATION, 2014, 20 : S247 - S248
  • [36] 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
    Tedesco-Silva, Helio, Jr.
    Vitko, Stefan
    Pascual, Julio
    Eris, Josette
    Magee, John C.
    Whelchel, John
    Civati, Giovanni
    Campbell, Scott
    Alves-Filho, Gentil
    Bourbigot, Bernard
    Garcia, Valter Duro
    Leone, John
    Esmeraldo, Ronaldo
    Rigotti, Paolo
    Cambi, Vincenzo
    Haas, Tomas
    TRANSPLANT INTERNATIONAL, 2007, 20 (01) : 27 - 36
  • [37] Efficacy and Safety of Everolimus With Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplant: Design of a Randomized Study.
    Grant, D.
    Levy, G.
    Song, G.
    Chen, C.
    Lee, W.
    Joh, J.
    Speziale, A.
    Rauer, B.
    Wang, Z.
    Junge, G.
    Uemoto, S.
    Suh, K.
    TRANSPLANTATION, 2014, 98 : 781 - 782
  • [38] EVEROLIMUS WITH REDUCED TACROLIMUS PRESERVES LONG-TERM RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS: 36 AND 48 MONTHS RESULTS FROM THE H2304E1 STUDY
    Saliba, F.
    Durand, F.
    Neau-Cransac, M.
    Hardwigsen, J.
    Pageaux, G.
    Lopez, P.
    Dong, G.
    Di Giambattista, F.
    Duvoux, C.
    TRANSPLANT INTERNATIONAL, 2016, 29 : 7 - 7
  • [39] HEPHAISTOS study: Early use of everolimus plus reduced tacrolimus in de novo liver transplant recipients achieves high efficacy and safety compared to standard tacrolimus.
    Schemmer, P.
    Nashan, B.
    Braun, F.
    Pascher, A.
    Klein, C. -G
    Neumann, U.
    Kroeger, I
    Wimmer, P.
    Schlitt, H. J.
    TRANSPLANTATION, 2019, 103 (08) : 298 - 298
  • [40] Everolimus With Reduced Tacrolimus Preserves Long-Term Renal Function in Liver Transplant Recipients: 36 and 48 Months Results From The H2304E1 Study
    Fung, J.
    Saliba, F.
    Kaiser, G.
    De Carlis, L.
    Metselaar, H.
    Nevens, F.
    Duvoux, C.
    De Simone, P.
    Fischer, L.
    Dong, G.
    Rauer, B.
    Junge, G.
    TRANSPLANTATION, 2014, 98 : 180 - 180
12345